Alkermes plc Reports Strong Q2 2026 Financial Results, Announces CEO Transition and Updates Guidance
Executive Summary
Alkermes plc (Nasdaq: ALKS) has released its Q2 2026 financial results, highlighting robust revenue growth, major pipeline developments, and a significant leadership transition. These developments and updated guidance contain price-sensitive information that investors and shareholders should closely monitor.
Key Financial Highlights
- Total Revenues: Q2 2026 revenues reached \$496.0 million, up from \$390.7 million in Q2 2025. Six-month revenues totaled \$888.9 million, up from \$697.2 million in the prior year.
- GAAP Net Income: Q2 2026 net income was \$0.5 million, significantly lower than \$87.1 million in Q2 2025. For the first six months, Alkermes reported a net loss of \$66.0 million versus net income of \$109.6 million in the prior year.
- Adjusted EBITDA: Q2 2026 Adjusted EBITDA was \$139.2 million, up from \$126.5 million in Q2 2025. Six-month Adjusted EBITDA reached \$219.5 million versus \$172.1 million in the prior year.
- Operating Expenses: SG&A expenses jumped to \$217.6 million in Q2 2026 (from \$170.8 million in Q2 2025), and R&D expenses increased to \$112.9 million (from \$77.4 million).
Proprietary Product Performance
- VIVITROL®: Q2 2026 revenues were \$124.5 million, with a favorable patient mix boosting gross-to-net results.
- ARISTADA®: Q2 2026 revenues were \$96.7 million. The quarter benefited from approximately \$4 million in gross-to-net favorability.
- LYBALVI®: Q2 2026 revenues were \$94.0 million. Revenues and prescriptions grew 12% and 18% year-over-year, respectively.
- LUMRYZ®: Q2 2026 revenues were \$96.6 million, including a \$7 million inventory benefit due to shipment timing. LUMRYZ was not part of the portfolio in Q2 2025, reflecting the impact of the Avadel acquisition.
- VUMERITY® Manufacturing and Royalty Revenues: \$30.6 million for the quarter.
- Royalty Revenue from Johnson & Johnson Products: \$27.5 million for the quarter (includes XEPLION®, INVEGA TRINZA®/TREVICTA®, INVEGA HAFYERA®/BYANNLI®).
- RISPERDAL CONSTA® Manufacturing Revenue: \$20.9 million for the quarter.
Balance Sheet & Liquidity
- Cash, Equivalents, and Investments: \$691.6 million as of June 30, 2026, up from \$538.2 million at March 31, 2026.
- Total Assets: \$4.39 billion at June 30, 2026, up from \$2.49 billion at December 31, 2025, reflecting the Avadel acquisition.
- Long-term Debt: \$1.48 billion, with \$26.5 million current portion.
- Shareholders’ Equity: \$1.81 billion.
Pipeline Progress & Strategic Updates
- Orexin 2 Receptor Agonist Portfolio: Alkermes positions this portfolio as a potentially transformational growth opportunity, targeting sleep medicine and other neurological disorders.
- Upcoming Data: First ADHD data for ALKS 7290 is expected in the coming months. Topline results from the alixorexton Phase 2 idiopathic hypersomnia study are expected toward year-end, potentially opening new opportunities for the orexin 2 portfolio.
- Avadel Acquisition: Closed February 12, 2026. LUMRYZ net sales guidance reflects only post-acquisition sales. Intellectual property from LUMRYZ will be amortized over 14 years.
Leadership Transition
- CEO Change: Blair Jackson will assume the CEO role on August 1, 2026. Richard Pops will remain Chairman. This transition is highlighted as a key strategic milestone aimed at sustaining momentum and growth.
2026 Guidance – Updated and Price Sensitive
- Total Revenue Guidance: \$1.73 billion – \$1.84 billion (unchanged from previous guidance).
- Product Net Sales Guidance:
- VIVITROL: \$460–\$480 million
- LYBALVI: \$380–\$400 million
- ARISTADA: \$365–\$385 million
- LUMRYZ: \$315–\$335 million (reflects Avadel acquisition impact)
- Cost of Goods Sold: \$320–\$340 million.
- R&D Expenses: \$445–\$485 million.
- SG&A Expenses: \$890–\$930 million.
- Amortization of Intangibles: \$75–\$85 million.
- Fair Value of Contingent Consideration: ~\$25 million (new, following positive LUMRYZ Phase 3 results in idiopathic hypersomnia).
- Net Interest Expense: \$75–\$85 million.
- GAAP Net Loss: Guidance revised to (\$95)–(\$115) million, increased from previous (\$70)–(\$90) million range, reflecting acquisition costs and inventory step-ups. This is a negative revision and may be share price sensitive.
- EBITDA: Guidance revised downward to \$75–\$95 million from \$105–\$135 million.
- Adjusted EBITDA: Guidance unchanged at \$370–\$410 million.
Note: The acquisition of Avadel introduces significant accounting and operational changes, including share-based compensation acceleration, inventory fair value step-ups, and contingent consideration adjustments. These are likely to impact near-term results and may affect future profitability.
Other Important Shareholder Information
- Conference Call: Alkermes will host a conference call and webcast at 8:00 a.m. ET (1:00 p.m. BST) on July 28, 2026, with slides available on their website. This may provide further insights and updates.
- Non-GAAP Measures: EBITDA and Adjusted EBITDA are presented for performance monitoring but are not GAAP liquidity measures. Investors should review reconciliations and underlying assumptions.
- Forward-Looking Statements: Management cautions that all projections are subject to risks, especially related to clinical trial outcomes, regulatory approvals, competitive landscape (including generics and pricing), and integration of Avadel.
Potential Share Price Drivers & Risks
- Positive: Strong revenue growth, pipeline advancements (orexin 2 agonists, LUMRYZ Phase 3 results), and leadership transition positioning the company for future growth.
- Negative: Downward revision of GAAP net loss and EBITDA guidance, increased operating expenses, and acquisition-related costs may impact near-term profitability and share price.
- Uncertainty: Success of upcoming clinical data (ADHD and idiopathic hypersomnia), regulatory decisions, and integration of Avadel.
Investors should closely monitor the upcoming conference call, pipeline updates, and execution of the integration and commercialization plans. Any surprises in clinical data, regulatory outcomes, or competitive developments could materially affect Alkermes’ valuation.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties detailed in Alkermes’ filings with the SEC. Investors are strongly urged to review official company filings and consult their financial advisors before making investment decisions.
